Intensive Case Management for Substance Use Disorders (RCT) (ICM)
Intensive Case Management for Patients With Substance Use Disorders and Complex Psychosocial Needs: A Randomized Controlled Trial
This study aims to assess the effectiveness of Intensive Case Management (ICM) compared to TAU. Economically, this study could contribute to more cost-effective treatments, since relatively expensive inpatient care could be relieved of patients not benefiting from inpatient care, and those patients would receive a more adequate and effective treatment. Our first goal is to evaluate the effectivenessof ICM as a treatment for people with SUDs in the canton of Aargau compared to TAU. To assess the effectiveness, the outcome measured will be the RICID and the NOIA. Furthermore, the increase in Quality of Life and Social Integration with appropriate Questionnaires of Patients in ICM is compared to Patients in TAU. The second goal of this study is to evaluate the cost-effectiveness of ICM for the aforementioned patients compared to TAU.
Case Management, especially for people with multiple and complex needs, is an intervention designed to enhance coordination and continuity of support and care (Vanderplasschen et al. 2019). Also, for people with high levels of disability due to mental illness, ICM is widely claimed to be an evidence-based and cost-effective program (King, 2006). Furthermore, key ICM components, linkage and retention, seem to show the largest effect sizes (SMD = 0.33, 95% CI 0.18-0.48) in ICM. Linkage and retention are necessary prerequisites that keep patients with SUDs in contact with health services (Vanderplasschen et al., 2019). Although evidence across all outcome measures, according to the same author, is significant and positive, but small (SMD = 0.18, 95% CI [0.07-0.28]). There is mixed evidence in outcomes such as health outcomes (SMD = -0.16, 95%CI [-0.40, 0.08]), social functioning (SMD = 0.14, 95% CI [-0.01, 0.28]) or reduced substance use (SMD = 0.10, 95% CI [-0.02, 0.21]).
Moreover, ICM and closely related models (i.e., Assertive Community Treatment, ACT) show a Reduction in Cumulative Inpatient Days (RICID) and a reduction in inpatient admissions (Dietrich et al., 2017; Burns et al., 2007). This is a common outcome in ICM literature and is also a measure for reductions in healthcare costs, since inpatient treatments are bound to high costs.
In this study, there are mainly four groups of patients with SUDs that, despite previous or present linkages to health services, do need further or a different kind of treatment. Those patients are:
- People with low treatment satisfaction and high usage of health and social services: These patients, despite their previous treatments and social connections, do not improve sufficiently and continue to utilize healthcare services.
- people that already are in complex helping systems and make use of a high number of treatments but show a high need for coordination to be effective
- patients with dual diagnosis, with SUD being one of those in combination with, e.g., schizophrenia, personality disorders and anxiety disorders and would need intense and continuous care.
- people that, due to their clinical picture or other difficulties in life, do not have access to existing treatments (anymore) and fall through the social network. It includes people without permanent addresses, people with precarious housing conditions or socially isolated people, independent of their employment status.
Sex and gender will be treated as potential covariates and will be considered in the analysis.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 해당 없음
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Johannes Senesi, MSc
- 전화번호: +41564622670
- 이메일: johannes.senesi@pdag.ch
연구 장소
-
-
Canton of Aargau
-
Windisch, Canton of Aargau, 스위스, 5210
- 모병
- PDAG
-
연락하다:
- Johannes Senesi, MSc
- 전화번호: +41564622670
- 이메일: johannes.senesi@pdag.ch
-
수석 연구원:
- Johannes Senesi, Msc
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- 4 or more inpatient admissions in the last 24 months
- Diangosed SUD
- Residence or temporary stay in the canton of Aargau
Exclusion Criteria:
- any emergency situation requiring psychiatric or hospital admissions
- inability to give informed consent
- acute, unstable psychotic symptoms
- acute risk of harm to self or others
- insufficient german language skills
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 건강 서비스 연구
- 할당: 무작위
- 중재 모델: 크로스오버 할당
- 마스킹: 하나의
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Experimental
receives ICM immediately |
Intensive Case Management for People with SUDs and complex psychosocial needs is an outreach-based intervention aimed at linking participants to health services and coordinating them. Additionally, two focus points are implemented to increase adherence and engagement:
|
|
활성 비교기: Waiting List
Same as Experimental, only with 6-Month TAU-Waiting List before ICM |
TAU will take place for 6 months before starting with ICM |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Number of Inpatient Admissions (Health Service utilisation)
기간: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
|
Number of Inpatient Admissions into psychiatric care. This measure only reflects the presence of patients on the ward and is strenghtend by Continuity of Care, Linking and Retention. |
6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
|
|
Number of Inpatient Days (Health Service utilisation)
기간: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
|
Number of Inpatient Days in psychiatric care. This measure only reflects the presence of patients on the ward and is strenghtend by Continuity of Care, Linking and Retention. |
6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
WHOQoL-BREF
기간: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
|
Quality of Life |
6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
|
|
SFQ
기간: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
|
Social Functioning Questionnaire |
6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
|
기타 결과 측정
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
ASSIST
기간: 6 Months (exploratory), 24 months (exploratory)
|
Substance use characteristics |
6 Months (exploratory), 24 months (exploratory)
|
|
Continuity of Care (Brice-Boxerman)
기간: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
|
Continuity of Care describes timeframes of the health services used outside the ward. |
6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
|
|
Linking
기간: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
|
Linking describes the successful referral to health services not captured by the primary endpoint (meaning, outside the ward) and is the central mechanism of this Intensive Case Management. |
6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
|
|
Retention
기간: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
|
Retention describes the voluntary staying of patients in the ICM treatment |
6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
|
|
BSCL
기간: 6 Months (exploratory), 24 months (exploratory)
|
Brief Symptoms Checklist, measuring the most common somatic and psychological symptoms found in psychiatric care |
6 Months (exploratory), 24 months (exploratory)
|
|
EQ-5D-5L
기간: 6 Months (exploratory), 24 months (exploratory)
|
EuroQOL Quality of Life questionnaire for assessing cost-effectiveness (Incremental cost-effectiveness ratio, ICER) |
6 Months (exploratory), 24 months (exploratory)
|
공동 작업자 및 조사자
협력자
협력자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- PDAG-ICM
- HumRes68440 (기타 식별자: Human Research Switzerland (HumRes))
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .